Exthera Medical Announces Initiation Of Clinical Trials Of Its Seraph Microbind Affinity Blood Filter (Seraph)

“We are delighted to report the start of human clinical trials of Seraph®, our revolutionary device designed to treat drug-resistant bloodstream infections.” Robert Ward, CEO

BERKELEY, Calif.--(BUSINESS WIRE)--ExThera Medical Corporation, the leading developer of broad-spectrum, dialysis-like devices to treat bloodstream infections, announced today that it has received approval of its CE mark clinical trial protocol from Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), the German Competent Authority. This approval, together with approval of the Ethics Committee of Hannover Medical School (also received), allows the company to begin its CE mark study in Hannover immediately. In this study Seraph will be used to treat dialysis patients who have Staphylococcus aureus and MRSA bloodstream infections. ExThera conducted a Clinical Site Initiation Meeting at Hannover in November and is awaiting enrollment of its first patient.

“Certain bloodstream infections have a mortality rate as high as 50% due to the lack of effective antibiotics. With fewer anti-infective drugs being developed, and the continuing emergence of drug- resistant pathogens, clinicians need new tools to fight bloodstream infections”

S. aureus and drug-resistant MRSA are the most common causes of infection in patients undergoing routine dialysis for kidney failure, and bloodstream infections are the second-most-common cause of death in end-stage renal disease patients because these infections can cause septic shock with multiple organ failure. Initially Seraph will be used for early treatment of bloodstream infections to prevent severe sepsis and reduce or eliminate ICU stays. Future clinical studies will concentrate on selected patients whose bloodstream infections have already progressed to severe sepsis or septic shock.

“Certain bloodstream infections have a mortality rate as high as 50% due to the lack of effective antibiotics. With fewer anti-infective drugs being developed, and the continuing emergence of drug- resistant pathogens, clinicians need new tools to fight bloodstream infections,” said Bob Ward, CEO, ExThera Medical.

ExThera Medical was the first to report the removal of bacteria from whole blood using a device instead of a drug. Early bench testing, and recent preclinical in vivo studies, have demonstrated that large amounts of MRSA are safely removed from blood as it passes through the Seraph device. ExThera has also published confirmation of Seraph’s ability to remove 99.9% of two Carbapenem-Resistant Enterobacteriaceae (‘CRE Superbugs’) — E. coli and Klebsiella pneumoniae — from blood after only brief contact with the Seraph adsorption media. Study results are published in the online journal PLOS ONE. In fact, Seraph may remove more than 60 different disease-causing bacteria, viruses and toxins, reported to bind to heparan sulfate and heparin, Seraph’s primary ligand.

Every year there are 1.8 million new cases of bloodstream infection in the U.S. and Europe, causing patients serious complications and imposing a high cost burden on health care systems. Not all are drug-resistant. However, an outbreak of CRE infections of unknown origin even occurred in the National Institutes of Health Hospital in Bethesda, and was the subject of the Frontline documentary, ”Hunting the Nightmare Bacteria.” Click here: “Hunting the Nightmare Bacteria” Frontline, PBS.

Since 2008, privately funded ExThera Medical has been developing Seraph^®, which is now being manufactured under ISO 13485 Quality System. It enters clinical trials as a totally unique broad-spectrum ‘hemoperfusion device’. Seraph has demonstrated its ability to bind and remove a long list of disease-causing agents from whole blood, including viruses, bacteria, fungi and inflammatory cytokines. Unlike other devices still in early-stage development, Seraph is easily manufactured in large quantities from readily available raw materials.

According to Dr. Keith McCrea, CTO of ExThera, “Since its inception ExThera’s mission has been to offer simple, device-based therapies for rapid treatment of bloodstream infections—including those caused by pathogens for which there are no effective therapeutic drugs. We are very pleased to make our device available to dialysis patients who are highly susceptible to bloodstream infections via their blood access catheters. Our preclinical testing has demonstrated that Seraph can be used during dialysis without negatively affecting the blood. We have also determined that Seraph acts very quickly to reduce the level of blood-borne pathogens, and has a binding capacity that greatly exceeds the entire bloodstream concentration of pathogens in bacteremic patients.”

Seraph uses a ‘biomimetic adsorption media’ that includes (chemically bound) heparin adsorbent materials in a simple, flow-through cartridge. The well-known anti-thrombogenic property of immobilized heparin also contributes to the safety of Seraph’s blood-contacting surface.

In addition to the potential to treat bacterial and viral infections for the prevention of sepsis, Seraph is a flexible platform that may be configured with optional supplemental adsorbents to deal with future ‘weaponized’, or naturally evolved, pathogens.

About ExThera Medical
Privately held ExThera Medical, based in Berkeley, Calif., is targeting the clinical treatment of blood- borne diseases including bacteremia and viremia, as well as the removal of other harmful substances present in human blood. While medical treatments of e.g., bacteremia caused by S. aureus or MRSA (Methicillin-Resistant S. aureus) usually rely on antibiotics, ExThera Medical’s Seraph® device capitalizes on the pathogen’s affinity to attach to immobilized heparin, a natural anticoagulant which has many other biological attributes. Seraph® is designed to be a biomimetic adjunct or alternative to anti-infective therapy for reducing pathogen and toxin load, and the duration of bloodstream infections, thereby preventing complications such as endocarditis, osteomyelitis, and a runaway systemic inflammatory response. The Company exhibited its Seraph device and delivered a technical presentation in September 2015 at the Sepsis Update Meeting in Weimar, Germany, sponsored by the German Sepsis Society.

CAUTION: ExThera Medical’s Seraph® device is not cleared by the FDA for distribution in the United States.

Disclaimer
All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release.